Atrium Therapeutics Shares Rise 5% in 1 Day Since ATR 1072 Reverses Cardiac Glycogen
Atrium Therapeutics (RNA) reports nonclinical data showing ATR 1072 reverses cardiac glycogen accumulation. Initial Phase 1/2 clinical data expected in H2 2027.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Atrium Therapeutics, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (2 Nov 2026). Not a valuation or a recommendation.
Down 15.5% over the last month ($7.61 on 19 Oct → $6.43 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $7.61 |
|---|---|
| 20 Oct | $7.98 |
| 21 Oct | $8.00 |
| 22 Oct | $8.16 |
| 23 Oct | $8.20 |
| 26 Oct | $8.05 |
| 27 Oct | $8.32 |
| 28 Oct | $8.40 |
| 29 Oct | $8.26 |
| 30 Oct | $8.27 |
| 2 Nov | $8.55 |
| 3 Nov | $8.72 |
| 4 Nov | $8.68 |
| 5 Nov | $8.32 |
| 6 Nov | $8.34 |
| 9 Nov | $8.38 |
| 10 Nov | $8.23 |
| 11 Nov | $7.96 |
| 12 Nov | $7.50 |
| 13 Nov | $7.51 |
| 16 Nov | $6.43 |
Atrium Therapeutics (RNA) reports nonclinical data showing ATR 1072 reverses cardiac glycogen accumulation. Initial Phase 1/2 clinical data expected in H2 2027.
Atrium Therapeutics (RNA) enters into a $50 million securities purchase agreement with institutional investors to advance its precision cardiology pipeline now.
Track Atrium Therapeutics, Inc. live
Get the next Atrium Therapeutics, Inc. SEC filing seconds after it lands.